Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hisun-Pfizer Pharmaceuticals Co. Ltd.

Latest From Hisun-Pfizer Pharmaceuticals Co. Ltd.

Deal Watch: Vertex Selects First Candidate Under CRISPR Gene-Editing Collaboration

Vertex hopes to develop CTX001 as a treatment for sickle cell disease and beta thalassemia. Allergan adds stalled uterine fibroid candidate in buyout of troubled Repros, Juno licenses multiple myeloma candidate from Lilly.

Deals M & A

Hisun-Pfizer Split: What Went Wrong And What Next?

The breakup of the Hisun-Pfizer JV typifies an unhappy marriage between Chinese and MNC pharma firms in the generics segment in recent years, although the two companies will continue to work as commercial partners under a new framework. Scrip delves into the reasons for the split and also outlines why, China is, nevertheless, expected to see more joint ventures for innovative drugs.

BioPharmaceutical China

Hangzhou’s Attractions Play Big Part In New Pfizer China Investment

The Hangzhou Economic Development Area has become a highly attractive spot for global pharmas to establish an expanded presence in China, as its integrated platforms, high quality talent pool and incentives help develop a powerhouse of high-end manufacturing. Pfizer’s $350m decision to join the industrial cluster for a new biotech center follows on from others including MSD, Lilly and Bayer.

BioPharmaceutical Asia Pacific

China Aiming To Slash Certain Cancer Drug Prices To Ease Access

Amid calls to expand access to costly patented cancer drugs, China is negotiating with several suppliers for the potential inclusion of selected targeted therapies in national reimbursement schemes. But could the potential benefits justify the likely 50% cuts?

BioPharmaceutical China
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Hisun-Pfizer Pharmaceuticals Co. Ltd.
  • Senior Management
  • Kevin Xiao, CEO
  • Contact Info
  • Hisun-Pfizer Pharmaceuticals Co. Ltd.
    ,
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register